Antiphospholipid Syndrome: The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).Antibodies, Antiphospholipid: Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.beta 2-Glycoprotein I: A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.Antibodies, Anticardiolipin: Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.Lupus Coagulation Inhibitor: An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.Catastrophic Illness: An acute or prolonged illness usually considered to be life-threatening or with the threat of serious residual disability. Treatment may be radical and is frequently costly.Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.Cardiolipins: Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS.Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.Syndrome: A characteristic symptom complex.Abortion, Habitual: Three or more consecutive spontaneous abortions.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Sneddon Syndrome: A systemic non-inflammatory arteriopathy primarily of middle-aged females characterized by the association of livedo reticularis, multiple thrombotic CEREBRAL INFARCTION; CORONARY DISEASE, and HYPERTENSION. Elevation of antiphospholipid antibody titers (see also ANTIPHOSPHOLIPID SYNDROME), cardiac valvulopathy, ISCHEMIC ATTACK, TRANSIENT; SEIZURES; DEMENTIA; and chronic ischemia of the extremities may also occur. Pathologic examination of affected arteries reveals non-inflammatory adventitial fibrosis, thrombosis, and changes in the media. (From Jablonski, Dictionary of Syndromes & Eponymic Diseases, 2d ed; Adams et al., Principles of Neurology, 6th ed, p861; Arch Neurol 1997 Jan;54(1):53-60)Anticoagulants: Agents that prevent clotting.Pregnancy Complications, Hematologic: The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Thrombophilia: A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Pregnancy Complications: Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.Skin Diseases, Vascular: Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.Plasmapheresis: Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.Prothrombin: A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.Abortion, Spontaneous: Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference.Pulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.HELLP Syndrome: A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.Fetal Death: Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.Thrombocytopenia: A subnormal level of BLOOD PLATELETS.Partial Thromboplastin Time: The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Meningism: A condition characterized by neck stiffness, headache, and other symptoms suggestive of meningeal irritation, but without actual inflammation of the meninges (MENINGITIS). Spinal fluid pressure may be elevated but spinal fluid is normal. (DeJong, The Neurologic Examination, 4th ed, p673)Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Blue Toe Syndrome: A condition that is caused by recurring atheroembolism in the lower extremities. It is characterized by cyanotic discoloration of the toes, usually the first, fourth, and fifth toes. Discoloration may extend to the lateral aspect of the foot. Despite the gangrene-like appearance, blue toes may respond to conservative therapy without amputation.Adrenal Insufficiency: Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.Lupus Vasculitis, Central Nervous System: Central nervous system vasculitis that is associated with SYSTEMIC LUPUS ERYTHEMATOSUS. Clinical manifestations may include DEMENTIA; SEIZURES; CRANIAL NERVE DISEASES; HEMIPARESIS; BLINDNESS; DYSPHASIA; and other neurological disorders.Copying Processes: Reproduction of data in a new location or other destination, leaving the source data unchanged, although the physical form of the result may differ from that of the source.Annexin A2: A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain.Phospholipids: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.Annexin A5: A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity.Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).Heparin, Low-Molecular-Weight: Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Phosphatidylserines: Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.Endocarditis: Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.Blood Coagulation Factors: Endogenous substances, usually proteins, that are involved in the blood coagulation process.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Infarction: Formation of an infarct, which is NECROSIS in tissue due to local ISCHEMIA resulting from obstruction of BLOOD CIRCULATION, most commonly by a THROMBUS or EMBOLUS.Puerperal Disorders: Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Antibodies, Antinuclear: Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.

Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. (1/684)

Antiphospholipid antibodies (aPL), anti-beta 2-glycoprotein I (anti-beta 2-GPI) and anti-oxidized-low-density lipoprotein (LDL) antibodies are all implicated in the pathogenesis of antiphospholipid syndrome. To investigate whether different autoantibodies or combinations thereof produced distinct effects related to their antigenic specificities, we examined the frequencies of antiphospholipid syndrome (APS)-related features in the presence of different antibodies [aPL, beta 2-GPI, anti-oxidized low density lipoprotein (LDL)] in 125 patients with APS. Median follow-up was 72 months: 58 patients were diagnosed as primary APS and 67 as APS plus systemic lupus erythematosus (SLE). Anticardiolipin antibodies (aCL), anti-beta 2-GPI and anti-oxidized LDL antibodies were determined by ELISA; lupus anticoagulant (LA) by standard coagulometric methods. Univariate analysis showed that patients positive for anti-beta 2-GPI had a higher risk of recurrent thrombotic events (OR = 3.64, 95% CI, p = 0.01) and pregnancy loss (OR = 2.99, 95% CI, p = 0.004). Patients positive for anti-oxidized LDL antibodies had a 2.24-fold increase in the risk of arterial thrombosis (2.24, 95% CI, p = 0.03) and lower risk of thrombocytopenia (OR = 0.41 95% CI, p = 0.04). Patients positive for aCL antibodies had a higher risk of pregnancy loss (OR = 4.62 95% CI, p = 0.001). When these data were tested by multivariate logistic regression, the association between anti-beta 2-GPI and pregnancy loss and the negative association between anti-oxidized LDL antibodies and thrombocytopenia disappeared.  (+info)

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. (2/684)

OBJECTIVE: To determine any HLA associations with anti-beta2-glycoprotein I (anti-beta2GPI) antibodies in a large, retrospectively studied, multiethnic group of 262 patients with primary antiphospholipid antibody syndrome (APS), systemic lupus erythematosus (SLE), or another connective tissue disease. METHODS: Anti-beta2GPI antibodies were detected in sera using an enzyme-linked immunosorbent assay. HLA class II alleles (DRB1, DQA1, and DQB1) were determined by DNA oligotyping. RESULTS: The HLA-DQB1*0302 (DQ8) allele, typically carried on HLA-DR4 haplotypes, was associated with anti-beta2GPI when compared with both anti-beta2GPI-negative SLE patients and ethnically matched normal controls, especially in Mexican Americans and, to a lesser extent, in whites. Similarly, when ethnic groups were combined, HLA-DQB1*0302, as well as HLA-DQB1*03 alleles overall (DQB1*0301, *0302, and *0303), were strongly correlated with anti-beta2GPI antibodies. The HLA-DR6 (DR13) haplotype DRB1*1302; DQB1*0604/5 was also significantly increased, primarily in blacks. HLA-DR7 was not significantly increased in any of these 3 ethnic groups, and HLA-DR53 (DRB4*0101) was increased in Mexican Americans only. CONCLUSION: Certain HLA class II haplotypes genetically influence the expression of antibodies to beta2GPI, an important autoimmune response in the APS, but there are variations in HLA associations among different ethnic groups.  (+info)

Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. (3/684)

OBJECTIVE: To develop diagnostic criteria for a familial form of antiphospholipid antibody syndrome (APS), identify families with >1 affected member, examine possible modes of inheritance, and determine linkage to potential candidate genes. METHODS: Family members of probands with primary APS were analyzed for clinical and laboratory abnormalities associated with APS. Families with > or =2 affected members were analyzed by segregation analysis and typed for candidate genetic markers. RESULTS: Seven families were identified. Thirty of 101 family members met diagnostic criteria for APS. Segregation studies rejected both environmental and autosomal recessive models, and the data were best fit by either a dominant or codominant model. Linkage analysis showed independent segregation of APS and several candidate genes. CONCLUSION: Clinical and laboratory criteria are essential to identify the spectrum of disease associated with APS. We believe a set of criteria was developed that can precisely define affected family members with APS. Modeling studies utilizing these criteria strongly support a genetic basis for disease in families with APS and suggest that a susceptibility gene is inherited in an autosomal dominant pattern. However, in these families, APS was not linked with HLA, Fas, or other candidate genes, including beta2-glycoprotein 1, HLA, T cell receptor beta chain, Ig heavy chain, antithrombin III, Fas ligand, factor V, complement factor H, IgK, and Fas.  (+info)

The intrarenal vascular lesions associated with primary antiphospholipid syndrome. (4/684)

Even 10 yr after the identification of the antiphospholipid syndrome (APS), renal involvement in the course of APS is still relatively unrecognized, and is probably underestimated. The association of anticardiolipin antibodies and/or lupus anticoagulant with the development of a vaso-occlusive process involving numerous organs is now confirmed. In a multicenter study, 16 cases of "primary" APS (PAPS) were found and followed for 5 yr or more, all with renal biopsy. In all 16 cases of PAPS, there was a vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal hyperplasia of interlobular arteries (12 patients), recanalizing thrombi in arteries and arterioles (six patients), and focal cortical atrophy (10 patients). In combination, these led to progressive destruction of the kidney, accelerated by acute glomerular and arteriolar microangiopathy in five patients. Focal cortical atrophy is a distinctive lesion, present in 10 biopsies, and likely represents the histologic and functional renal analogue to the multiple cerebral infarcts detected on imaging studies. The clinical hallmark of this vascular nephropathy in PAPS is systemic hypertension, only variably associated with renal insufficiency, proteinuria, or hematuria. The ensemble of histologic renal lesions defined in this study should aid in the separation of the lesions found in cases of secondary APS, especially systemic lupus erythematosus, into those lesions related to APS and those related to the underlying disease.  (+info)

Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome. (5/684)

Mycoplasma penetrans, a rare bacterium so far only found in HIV-infected persons, was isolated in the blood and throat of a non-HIV-infected patient with primary antiphospholipid syndrome (whose etiology and pathogenesis are unknown).  (+info)

Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion. (6/684)

We describe the case of a 39-year-old woman who suffered two iliofemoral venous thromboses, a cerebral ischemic infarct and recurrent fetal loss. Initial studies showed high levels of antiphospholipid antibodies (APAs) and a moderate thrombocytopenia. After her second miscarriage, laboratory diagnosis revealed that the woman was heterozygous for the factor V Leiden mutation and had a functional protein S deficiency as well as anti-protein S and anti-beta 2-glycoprotein I antibodies. The impairment of the protein C pathway at various points could well explain the recurrent thromboses in the patient and supports the role of a disturbed protein C system in the pathophysiology of thrombosis in patients with APAs.  (+info)

Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. (7/684)

The present study was designed to investigate the effects of immunoglobulin G obtained from patients with antiphospholipid syndrome (APS) on in-vitro models of trophoblast invasiveness and differentiation. We tested the binding of affinity-purified immunoglobulin G to human primary trophoblast cells. These antibodies affected the invasiveness and differentiation of cytotrophoblast cells after binding to the cell surface. In addition, we determined whether the drugs used to treat APS might be able to restore the trophoblast functions. Low-molecular weight heparin, in a dose-dependent manner, significantly reduced the immunoglobulin G binding to trophoblast cells and restored in-vitro placental invasiveness and differentiation. No effect was observed in the presence of acetylsalicylic acid. These observations may help in understanding the role of these treatments in women with APS.  (+info)

Flank ulcer in a patient with primary antiphospholipid syndrome. (8/684)

A 32-year-old woman had a recurrent shallow ulcer on the flank. A biopsy specimen showed thromboses in the dermal vessels and she was found to have circulating antiphospholipid antibody with no associated systemic disease. A clean ulcer developed on the flank of a patient with primary antiphospholipid syndrome is considered to be a rarely encountered/unusual presentation of this syndrome.  (+info)

*Antiphospholipid syndrome

... or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused ... Primary antiphospholipid syndrome occurs in the absence of any other related disease. Secondary antiphospholipid syndrome ... Antiphospholipid syndrome is an autoimmune disease, in which "antiphospholipid antibodies" (anticardiolipin antibodies and ... CAPS or Asherson syndrome) and is associated with a high risk of death. Antiphospholipid syndrome often requires treatment with ...

*Systemic lupus erythematosus

"Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome". Neurol. Neurochir ... Abnormalities associated with antiphospholipid antibody syndrome include a paradoxical prolonged partial thromboplastin time ( ... 2003). "Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment ... People with SLE may have an association with antiphospholipid antibody syndrome (a thrombotic disorder), wherein autoantibodies ...

*Venous thrombosis

... particularly by air Pregnancy and the postpartum period Antiphospholipid syndrome (such as lupus anticoagulant) Trauma and ... oral Central venous catheters Inflammatory diseases/some autoimmune diseases Nephrotic syndrome Obesity Infection HIV ...

*Recurrent miscarriage

... to determine if they have antiphospholipid syndrome. Women diagnosed with antiphospholid syndrome generally take aspirin or ... The antiphospholipid syndrome is an autoimmune disease that is a common cause of recurrent pregnancy loss. Around 15% of the ... anticoagulants seem to increase the live birth rate among those with antiphospholipid syndrome and perhaps those with ... Women with polycystic ovary syndrome also have higher loss rates possibly related to hyperinsulinemia or excess androgens. ...

*Lupus anticoagulant

... criteria specify that both serological and functional tests must be positive to diagnose the antiphospholipid antibody syndrome ... Current evidence suggests that the risk of recurrent thrombosis in patients with an antiphospholipid antibody is enhanced ... as well as serological testing to identify common autoantibodies such as antiphospholipid antibodies. These antibodies tend to ... "Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant" (PDF). The Cochrane ...

*Systemic lupus erythematosus and pregnancy

Later losses appear to occur primarily due to the antiphospholipid syndrome, in spite of treatment with heparin and aspirin. ... All women with lupus, even those without previous history of miscarriage, are recommended to be screened for antiphospholipid ... thrombocytopenia of the HELLP syndrome may appear like that of SLE, and pregnancy-related edema of joints can appear like ...

*Antiphospholipid syndrome, familial

... is a protein that in humans is encoded by the ATPLS gene. "Human PubMed Reference:". " ...

*Catastrophic antiphospholipid syndrome

... (CAPS), also known as Asherson's syndrome, is an acute and complex biological process ... "The Catastrophic Antiphospholipid (Asherson's) Syndrome". Autoimmunity Reviews 2005; 5:48-54. [1] Hughes Syndrome foundation [2 ... and in some cases tissue necrosis and is considered an extreme or catastrophic variant of the antiphospholipid syndrome. CAPS ... Clinically, the syndrome affects at least three organs and may affect many organs systems. Peripheral thrombosis may be ...

*DMOZ - Health: Conditions and Diseases: Immune Disorders: Auto-Immune: Antiphospholipid Syndrome

A look at antiphospholipid antibody syndrome, what laboratory tests can support the diagnosis of this syndrome, what are the ... The Hughes Syndrome Foundation Information about antiphospholipid syndrome, the symptoms, diagnosing and treatment. Also ... "Health ... Antiphospholipid Syndrome" search on: AOL - Ask - Bing - DuckDuckGo - Gigablast - Google - ixquick - Yahoo - Yandex ... The Antiphospholipid Syndrome By Sara Marder, M.D. An explanation of this order and its association with pregnancy loss, who ...

*Brandon Holiday

"Antiphospholipid syndrome". Wikipedia. 2017-02-10. "Paracanoe". Wikipedia. 2017-01-19. http://sunshinepando.com/2016/05/brandon ... He also grew up with Systemic Lupus, Primary Addison's and a blood clotting condition (Antiphosolipid Syndrome). After ...

*Yehuda Shoenfeld

The Antiphospholipid Syndrome II : Autoimmune Thrombosis. by Ricard Cervera (Editor), Ronald A. Asherson, Jean-Charles Piette ( ... The Antiphospholipid Syndrome. by Ricard Cervera (Editor), Ronald A. Asherson (Editor), Jean-Charles Piette (Editor), Yehuda ... Health care in Israel Session 13, Vaccine Safety Conference, Jamaica, 2011, "Autoimmune (Auto-Inflammatory)Syndrome Induced by ... Adjuvant: A New Syndrome to be Defined" Autoimmunity Congress, Through The Eyes of Participants and Professor Shoenfeld ...

*Russell's viper

Antiphospholipid Syndrome at SpecialtyLaboratories. Retrieved 27 September 2006. Rodrigo M (2016). Trials to start for home- ... Tunpe (1987). "Acute and Chronic Pituitary Failure Resembling Sheehan's Syndrome Following Bites by Russell's Viper in Burma". ... resembling Sheehan's syndrome: First case report from Sri Lanka, a review of the literature and recommendations for endocrine ... "Acute and chronic pituitary failure resembling Sheehan's syndrome following bites by Russell's viper in Burma". Lancet. 2 (8562 ...

*Low-density lipoprotein receptor-related protein 8

Antiphospholipid syndrome is an autoimmune disease characterized by thrombosis and complications during pregnancy, often ... doi:10.1016/B978-012370509-9.00015-2. de Groot PG, Derksen RH (August 2005). "Pathophysiology of the antiphospholipid syndrome ...

*Secondary hypertension

D'Cruz D (February 2009). "Renal manifestations of the antiphospholipid syndrome". Current Rheumatology Reports. 11 (1): 52-60 ... of patients with Cushing's syndrome develop hypertension., which is accompanied by distinct symptoms of the syndrome, such as ... liddle's syndrome (also called pseudoaldosteronism), glucocorticoid remediable aldosteronism Cushing's syndrome - an excessive ... Cushing's syndrome can be caused by taking glucocorticoid drugs, or by tumors that produce cortisol or adrenocorticotropic ...

*Phenothiazine

Use of phenothiazines has been associated with antiphospholipid syndrome, but no causal relationship has been established. ... PMID 22580516 "Antiphospholipid Syndrome - Doctor's Information , Patient". Patient. Retrieved 2015-07-25. "Electrocatalytic ... and the rare but potentially fatal neuroleptic malignant syndrome, as well as substantial weight gain. ...

*Thrombotic storm

"The catastrophic antiphospholipid syndrome 1996: Acute multi-organ failure associated with antiphospholipid antibodies: A ... Triplett, Douglas A.; Asherson, Ronald A. (2000). "Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS)". ... other than Antiphospholipid syndrome) Treatment for Thrombotic Storm may include lifelong anticoagulation therapy and/or ... "Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three Cases". Seminars in Arthritis and Rheumatism. 37 (6): 366-72 ...

*Dilute Russell's viper venom time

Antiphospholipid antibody syndrome is an important marker for recurrent thrombosis, and often warrants indefinite anticoagulant ... 2008). "Laboratory Evaluation of the Antiphospholipid Syndrome". Hematol Oncol Clin North Am. 22 (1): 19-32. doi:10.1016/j.hoc. ... Kaul M, Erkan D, Sammaritano L, Lockshin MD (July 2007). "Assessment of the 2006 revised antiphospholipid syndrome ... 2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome ( ...

*Warfarin

"Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome". Pharmacotherapy. 23 (5): ... Warfarin is also used in antiphospholipid syndrome. It has been used occasionally after heart attacks (myocardial infarctions ... Less common side effects may include areas of tissue damage and purple toes syndrome. Use is not generally recommended during ... is purple toe syndrome. This condition is thought to result from small deposits of cholesterol breaking loose and causing ...

*Nonsteroidal anti-inflammatory drug

Cervera R, Balasch J (2004). "The management of pregnant patients with antiphospholipid syndrome". Lupus. 13 (9): 683-7. doi: ... NSAIDs may be used with caution by people with the following conditions: Irritable bowel syndrome Persons who are over age 50, ... Ibuprofen may also rarely cause irritable bowel syndrome symptoms. NSAIDs are also implicated in some cases of Stevens-Johnson ... In rarer instances NSAIDs may also cause more severe kidney conditions: Interstitial nephritis Nephrotic syndrome Acute kidney ...

*Heparin-induced thrombocytopenia

Warkentin TE, Aird WC, Rand JH (2003). "Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome". ...

*Mycoplasma penetrans

1999). "Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome". Emerging Infectious Diseases. 5 (1): 164-7. doi ...

*Bleeding diathesis

Another example is antiphospholipid syndrome an autoimmune, hypercoagulable state. Bleeding diathesis may also be caused by ... Wiskott-Aldrich Syndrome The International Patient Organisation for Primary Immunodeficiencies (IPOPI). Disorders of thrombosis ... Viral hemorrhagic fevers include dengue hemorrhagic fever and Dengue Shock Syndrome Leukemia may also cause coagulopathy. ... Wiskott-Aldrich syndrome and Glanzmann's thrombasthenia. Following are some complications of coagulopathies, some of them ...

*Steven Krilis

Krilis specializes in the treatment and research of Antiphospholipid syndrome. His laboratory was the first to recognise the ... recurrent miscarriages and Antiphospholipid syndrome. Among his over 120 peer-reviewed papers, the most cited are: McNeil, H.P ... "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)" ( ... McNeil, H.P., Chesterman, C.N., Krilis, S.A. "Immunology and clinical importance of antiphospholipid antibodies" (1991) ...

*Amaurosis fugax

"Transient visual symptoms in systemic lupus erythematosus and antiphospholipid syndrome". Ocul. Immunol. Inflamm. 9 (1): 49-57 ... Ocular ischemic syndrome Amaurosis Hemianopsia Fisher CM (December 1989). "'Transient monocular blindness' versus 'amaurosis ... Thrombocytosis Subclavian steal syndrome Malignant hypertension can cause ischemia of the optic nerve head leading to transient ... "Eosinophilic vasculitis leading to amaurosis fugax in a patient with acquired immunodeficiency syndrome". Arch. Intern. Med. ...

*Acrocyanosis

Unless acrocyanosis results from another condition (e.g. malignancy, antiphospholipid syndrome, atherosclerosis, acute ischemic ... Other causative conditions include infections, toxicities, antiphospholipid syndrome, cryoglobulinemia, neoplasms. In these ... blue finger syndrome. The diagnosis may be challenging in some cases, especially when these syndromes co-exist. Acrocyanosis ... "Association of acrocyanosis with Asperger's syndrome". Journal of mental deficiency research. 34 (1): 87-90. PMID 2325122. ...

*Michael D. Lockshin

He is a researcher of autoimmune diseases, with focus on antiphospholipid syndrome and lupus. He is currently Professor of ... antiphospholipid syndrome (APS), pregnancy in rheumatic disease patients, gender and rheumatic disease, and neurological SLE. ... and many research papers on the antiphospholipid antibody syndrome. He convened the first International Conference on Pregnancy ...

*Abdominal angina

Choi BG, Jeon HS, Lee SO, Yoo WH, Lee ST, Ahn DS (2002). "Primary antiphospholipid syndrome presenting with abdominal angina ... It can be associated with: carcinoid aortic coarctation antiphospholipid syndrome Internationally: Extremely rare. True ...
Antiphospholipid antibodies occur in various clinical states, including the primary antiphospholipid syndrome. Clinical features in these conditions appear to be caused by vasculopathy associated with the presence of these antibodies.. We report the case of a patient with primary antiphospholipid syndrome who experienced cardiac necrosis secondary to myocardial microvasculopathy in the absence of vasculitis. This case demonstrates unequivocally that noninflammatory myocardial microvasculopathy occurs in the primary antiphospholipid syndrome per se without any clinical or immunologic signs of systemic lupus erythematosus or other disease process. The histopathologic findings in the skin and myocardial biopsies showed a noninflammatory vasculopathy characterized by bland thrombi and lack of infiltration of the vessel wall by inflammatory cells. Ultrastructural examination of the myocardial biopsy confirmed the vascular thrombosis and endothelial activation and showed no deposits in basement ...
Antiphospholipid antibody syndrome: Find the most comprehensive real-world symptom and treatment data on antiphospholipid antibody syndrome at PatientsLikeMe. 640 patients with antiphospholipid antibody syndrome experience fatigue, Pain, depressed mood, anxious mood, and insomnia and use Aspirin, Hydroxychloroquine, Warfarin, Enoxaparin, and Oxycodone to treat their antiphospholipid antibody syndrome and its symptoms.
OBJECTIVE To determine the prevalence of cardiac valvular involvement in patients with the primary antiphospholipid syndrome. DESIGN Cross-sectional study with evaluation of case patients and control patients by Doppler echocardiography. The mean follow-up for case patients was 22 months. SETTING University-based tertiary medical center. PATIENTS Twenty-eight consecutive patients who were diagnosed with the primary antiphospholipid syndrome during a 10-year period; 28 age- and sex-matched healthy controls. MEASUREMENTS AND MAIN RESULTS Ten patients (36%; 95% Cl, 19% to 56%) with the primary antiphospholipid syndrome had cardiac valvular involvement: Four patients had mitral valve involvement; four patients, aortic valve involvement; and two patients, both mitral and aortic valvular involvement; no patients had tricuspid or pulmonary valve disease. Eight of 10 patients had a regurgitant murmur. None of the control patients had valvular disease. The mean mitral valve thickness in patients with
Antiphospholipid syndrome is an autoimmune disease, in which "antiphospholipid antibodies" (anticardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes. Like many autoimmune diseases, it is more common in women than in men. The exact cause is not known, but activation of the system of coagulation is evident. Clinically important antiphospholipid antibodies (those that arise as a result of the autoimmune process) are associated with thrombosis and vascular disease. The syndrome can be divided into primary (no underlying disease state) and secondary (in association with an underlying disease state) forms. Anti-ApoH and a subset of anti-cardiolipin antibodies bind to ApoH, which in turn inhibits Protein C, a glycoprotein with regulatory function upon the common pathway of coagulation (by degradating activated factor V). Lupus anticoagulant (LAC) antibodies bind to prothrombin, thus increasing its cleavage to thrombin, its active ...
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
Donadini, MP, Crowther, M. "Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations". Hematol-Oncol. vol. 24. 2010. pp. 669-76. (Recent concise review and update of this syndrome. Many of the clinical statistics were cited from this review.). Ruiz-Irastorza, G, Crowther, M, Branch, W, Khamashta, MA. "Antiphospholipid syndrome". Lancet. vol. 376. 2010. pp. 1498-1509. (Along with the first listed reference, a key source for this chapter, especially with respect to treatment recommendations.). Frances, C. "Dermatological manifestations of Hughes antiphospholipid antibody syndrome". Lupus. vol. 19. 2010. pp. 1071-77. (Current review of cutaneous manifestations.). Weinstein, S, Piette, W. "Cutaneous manifestations of antiphospholipid antibody syndrome". Hematol Oncol Clinics N Am. vol. 22. 2008. pp. 67-77. (Relatively recent review of cutaneous findings.). Hughes, GRV. "Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics". Lupus. vol. 19. 2010. pp. ...
TY - JOUR. T1 - Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis. AU - Chamsi-Pasha, Mohammed A.. AU - Alyousef, Tareq. AU - Sayyed, Samer H. PY - 2014/1/1. Y1 - 2014/1/1. N2 - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly limited. We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy. (Echocardiography 2014;31:E278-E281).. AB - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly ...
Antiphospholipid antibody syndrome is a fascinatingly complex disorder. It is an autoimmune disease, whereby the immune system attacks our own tissues. This article summarises the basic mechanisms of the condition and main diseases it is involved in. Learn about the diverse effects antiphospholipid antibody syndrome (APS) can have, from heart attack to miscarriage and how APS can be treated.
This guideline reviews the features of the Antiphospholipid syndrome [APS]- definition, clinical association, pathophysiology and the laboratory detection of Antiphospholipid antibodies. It includes a section on who should be tested for aPL antibodies and how this should influence their management. It also includes sections on the management of APS and the Catastrophic Antiphospholipid syndrome [CAPS].. ...
Rationale: Antiphospholipid syndrome (APS) in pregnancy may trigger the life-threatening catastrophic antiphospholipid syndrome (CAPS). Complement activation is implicated in the pathogenesis, and inhibition of complement factor C5 is suggested as an additional treatment option. Patient concerns, diagnosis and interventions: We present a pregnant patient treated with the C5-inhibitor eculizumab due to high risk of developing devastating APS-related complications. The complement inhibitory effects of the treatment were examined both in the patient and the premature infant. Outcomes: Complement activity in the mother recovered considerably faster than anticipated; however, no new thrombosis or CAPS developed during the last week of pregnancy or postpartum. Blood sampling from the umbilical vein and artery, and from the infant after delivery showed low complement activity; however, only 0.3% of the eculizumab concentration detected in the mother, consistent with low placental passage of eculizumab. ...
Introduction:Women with antiphospholipid syndrome(APS) may suffer from recurrent miscarriage, fetal death, fetal growth restriction (FGR), pre-eclampsia, placental abruption, premature delivery and thrombosis. Treatment with aspirin and low molecular weight heparin (LMWH) combined with close maternal-fetal surveillance can change these outcomes. Objective: To assess maternal and perinatal outcome in a cohort of Portuguese women with primary APS. Patients and Methods: A retrospective analysis of 51 women with primary APS followed in our institution (January 1994 to December 2007). Forty one(80.4%) had past pregnancy morbidity and 35.3%(n=18) suffered previous thrombotic events. In their past they had a total of 116 pregnancies of which only 13.79 % resulted in live births. Forty four patients had positive anticardiolipin antibodies and 33 lupus anticoagulant. All women received treatment with low dose aspirin and LMWH. Results: There were a total of 67 gestations (66 single and one multiple). The ...
OBJECTIVE: To characterize the clinical manifestations of patients with antiphospholipid antibody syndrome (APS) and pulmonary hemorrhage (PH). METHODS: We performed a retrospective, single-center analysis of patients with APS who were followed up fr
TY - JOUR. T1 - Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia [9]. AU - Holtan, Shernan G.. AU - Knox, S. K.. AU - Tefferi, Ayalew. PY - 2006/7. Y1 - 2006/7. UR - http://www.scopus.com/inward/record.url?scp=33745225893&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=33745225893&partnerID=8YFLogxK. U2 - 10.1111/j.1538-7836.2006.01961.x. DO - 10.1111/j.1538-7836.2006.01961.x. M3 - Article. C2 - 16839370. AN - SCOPUS:33745225893. VL - 4. SP - 1632. EP - 1634. JO - Journal of Thrombosis and Haemostasis. JF - Journal of Thrombosis and Haemostasis. SN - 1538-7933. IS - 7. ER - ...
Home Care in Prior Lake MN: June is Antiphospholipid Antibody Syndrome Awareness Month, which was created to get people talking about the dangers this disease poses for people of all ages.
NorthShore encourages patients to utilize our medical library. Read our Antiphospholipid antibody syndrome encyclopedia resources online.
Amaduzzi, Francesco and Bontempo, Giovanni and Francolini, Giancarlo and Frausini, Gabriele (2009) Antiphospholipid antibody syndrome. Functional Neurology; New Trends in Interventional Neurosciences, 24 (S1). pp. 70-71. ISSN 1971-3274 ...
Antiphospholipid antibody syndrome should be suspected in a patient with unprovoked venous and arterial thromboses, especially in a young patient without provocation. Testing can also be considered in women with histories of pregnancy loss, intrauterine growth restriction, preeclampsia, and abruption in settings in which antiphospholipid syndrome is suspected (testing should be limited to lupus anticoagulant, anticardiolipin Ab, and beta 2 glycoprotein Ab). -Diagnosis is based on clinical criteria of thromboses or pregnancy morbidity in the presence of antiphospholipid antibodies. The antiphospholipid antibodies used in the Sapporo classification are anticardiolipin (IgG and IgM), anti-beta2-glycoprotein (IgG or IgM), and lupus anticoagulant. Repeat confirmatory laboratory testing of the above antiphospholipid antibodies should be confirmed ,= 12 weeks apart. -Remember that you need clinical features and laboratory features to diagnosis antiphospholipid antibody syndrome. Thus, there is no value ...
BACKGROUND Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by vascular thrombosis (arterial or venous) and/or pregnancy complications associated with the occurrence of autoantibodies, specifically lupus anticoagulant, anticardiolipin antibodies, and/or anti-β2 glycoprotein-I antibodies confirmed at least twice over a 12 week period according to the 2006 Sydney criteria. Antiphospholipid antibodies are encountered in the general population with a reported prevalence of 1% to 5% However, APS is far more infrequent with a prevalence of 40-50/100,000 persons and an incidence of about 5 new patients/100,000 persons. APS can be diagnosed in patients with no apparent clinical or laboratory pathology (primary APS) or it may be related to numerous other conditions, autoimmune diseases (usually systemic lupus erythematosus), malignancies, infections and drugs (secondary APS). Women are at risk for APS since the disease is encountered in both the primary and the secondary state
Antiphospholipid syndrome is an autoimmune disease. This happens when your immune system fights against normal cells. This condition may also be called Hughes syndrome, sticky blood syndrome, and antiphospholipid antibody syndrome.
Also called Hughes syndrome, the results of antiphospholipid syndrome can be catastrophic for a pregnant woman. Learn about antiphospholipid syndrome symptoms and prognosis, as well as how it relates to pregnancy complications like miscarriage and premature birth.
Antiphospholipid syndrome is an autoimmune disease in which the body produces large amounts of antiphospholipid antibodies. Phospholipids are a special type of fat containing phosphate that makes up the outer walls of the bodys cells. Antiphospholipid antibodies attack the phospholipids. This causes many different problems including increased blood clotting. Cardiolipin is one type of phospholipid and specific anticardiolipin antibodies may develop.. This disease is about two times more common in women than men. It is generally characterized by the following:. ...
Schmeding and Schneider [57] reviewed the literature from 2000-2010 on the QOL of patients with SLE. It has been shown to lower QOL in patients with SLE vs. patients with other chronic diseases. SLE significantly reduces patients ability to cope with everyday activities. It is conditioned by age, fatigue and coexistence of neurological and psychiatric disorders, depression and irritability. There was no direct correlation between the degree of disease activity and organ damage in SLE and QOL.. Choi et al. [58] evaluated that the QOL of patients with SLE was lower than the control group, consisting healthy people. Reduced QOL resulted in depression, taking GCS and fatigue, which was not the result of the degree of disease activity and organ damage. Understanding psychological problems and appropriate treatment can help to improve the QOL of patients with SLE, especially those taking high doses of glucocorticosteroids, even if the disease activity is low. The study included 108 patients with SLE, ...
1. Yamaguchi Y, Noriyuki N, Kaburaki J, et al. Excesive exposure to aninic surfaces maitains autoantiboy response to B2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007;110:4312-18. 2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4:205-306. 3. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J. 1983;287:1088-9.. 4. Alijotas-Reig J. Towards the comprehension of heterogeneity of clinical manifestations related to antiphospholipid antibodies. Med Clin (Barc) 2005;125:187-89. 5. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic non-autoimmune women with unexplained recurrent primary early fetal loss. The Nimes Obstericians and Haematologists study-NOHA. Thromb Haemost 2000;84:228-236. 6. Asherson RA, Cervera R, Shepshelovich D, et al. Nonthrombotic manifestations ...
Thrombosis and pregnancy loss are common features of systemic lupus erythematosus (SLE), particularly in the presence of antiphospholipid (aPL) antibodies. The in vivo mechanisms by which aPL antibodies lead to vascular events and, specifically, to recurrent fetal loss are largely unknown. Studies in a mouse model of antiphospholipid antibody syndrome (APS) indicate that in vivo complement activation is necessary for fetal loss caused by aPL antibodies. This study represents an effort to translate these research observations on the potential role of complement activation in the pathogenesis of aPL antibody-mediated pregnancy loss to a clinically relevant human study.. In addition, studies in humans and mice have shown 1) that the balance of circulating angiogenic and antiangiogenic factors predicts preeclampsia and fetal growth restriction in healthy women, 2) circulating antiangiogenic factors cause endothelial dysfunction and abnormal placental development in animal models, and 3) complement ...
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature as well as obstetrical complications. The pathophysiological hallmark is thrombosis, but other factors such as complement activation might be important. Prevention of thrombotic manifestations associated with APS includes lifestyle changes and, in individuals at high risk, low-dose aspirin. Prevention and treatment of thrombotic events are dependent mainly on the use of vitamin K antagonists. Immunosuppression and anticomplement therapy have been used anecdotally but have not been adequately tested. Pregnancy morbidity includes unexplained recurrent early miscarriage, fetal death and late obstetrical manifestation such as pre-eclampsia, premature birth or fetal ...
During the past 12 years both clinicians and researchers involved in rheumatology, haematology, clinical immunology, and gynaecology have been inundated with hundreds of manuscripts regarding the so called antiphospholipid syndrome (APS).. As a result of the spread of information about the pathogenesis and clinical aspect of antiphospholipid antibodies (APA) in humans, non-professional APA readers have been often puzzled by APA characterisation, criteria for APS definition, reliability of assays for APA detection, and APS management.. None the less, thanks to the growing number of clinical findings concerning APS, it has became apparent that understanding of this syndrome may be of interest to other medical specialties.. Asherson and colleagues faced the difficult task of going through the great amount of information on APS and to present it in a systematic and didactic way.. The book is homogeneously structured in three sections dealing with aetiopathogenic mechanisms of APS (section I), its ...
Antiphospholipid syndrome is a systemic autoimmune disorder. It is usually defined as the clinical complex of vascular occlusion and ischaemic events occurring in patients who have circulating antiphospholipid antibodies. Pathology Patients hav...
Outcome of primary antiphospholipid syndrome in childhood. Gattorno, M.; Falcini, F.; Ravelli, A.; Zulian, F.; Buoncompagni, A.; Martini, G.; Resti, M.; Picco, P.; Martini, A. // Lupus;2003, Vol. 12 Issue 6, p449 The objective of this paper is to investigate the long-term outcome of primary antiphospholipid syndrome (APS) in the paediatric age. The features of unselected patients with primary APS who had disease onset before the age of 16 years were retrospectively analysed in three Italian referral... ...
The classical clinical picture of the antiphospholipid syndrome (APS) is characterized by venous and arterial thromboses, fetal losses and thrombocytopenia, in the presence of antiphospholipid...
The patient was referred for the antiphospholipid syndrome. Atypical findings-dorsalgia, cervical lymphadenopathy, fever, and weight loss-led to further work-up. Bronchoscopy showed a tracheal lesion that was negative on biopsy; node smears were also negative. Magnetic resonance imaging demonstrated a T3 image, which was diagnosed on biopsy as mucosecreting carcinoma metastasis. Mechanical hemolysis (regenerative anemia with schistocytes, negative results on the Coombs test, and low haptoglobin level) and disseminated intravascular coagulation were evident. Serum CA15.3 level was extremely elevated. Lupus anticoagulant and high levels of IgG anticardiolipin antibodies were present, without antibodies to β2-glycoprotein I. The patient died after developing left hemiparesis and respiratory distress. Autopsy confirmed carcinoma of unknown origin with lung miliary, thrombotic nonbacterial mitral vegetations, and renal and cerebral infarctions ...
APS is an autoimmune disorder that causes an increased risk for developing a venous or arterial thromboembolism, as well as recurrent miscarriages. APS frequently occurs in people with lupus, and is referred to as secondary APS in this case. Many people who have APS, however, do not have another autoimmune disorder, and their disease is referred to as primary APS. APS may be a genetic disorder, and identifying the gene(s) that predisposes an individual to develop it could lead to a better understanding of the disease, as well as improved therapies. This study will use a genetic strategy to identify potential risk factors for the development of APS by recruiting people with APS who have family members who are either affected by the syndrome or who have another autoimmune disorder. The results of the genetic testing will be compared among the following two groups of families: people with APS who also have one or more of their family members affected specifically by APS; and people with APS who ...
Journal of Immunology Research is a peer-reviewed, Open Access journal that provides a platform for scientists and clinicians working in different areas of immunology and therapy. The journal publishes research articles, review articles, as well as clinical studies related to classical immunology, molecular immunology, clinical immunology, cancer immunology, transplantation immunology, immune pathology, immunodeficiency, autoimmune diseases, immune disorders, and immunotherapy.
A 32-year-old woman was admitted for mild gait difficulty and behavioural changes of 3 years duration. Familial and medical histories were unremarkable. Neurological examination revealed: mildly slowed gait, decreased synkinesias of the left arm (held abducted and flexed), increased deep tendon reflexes, Babinski signs, mild lower limb spasticity and dysmetria of left limbs. Depression and mild executive dysfunctions were also found.. Brain CT showed cerebral white matter (WM) calcifications (fig 1). MRI revealed T2 WM hyperintensities in the centra semiovalia, around the frontal horns and, to a lesser extent, in the posterior regions. Post-contrast MRI demonstrated points and stripes of enhancement in the periventricular WM, which are consistent with engorged medullary vessels (fig 2). Proton ...
Find and save ideas about Lupus anticoagulant on Pinterest. | See more ideas about Antiphospholipid syndrome, Lupus antibodies and Lupus facts.
Blood. 117(25), 6939-6947. Agar C, de Groot PG, Marquart JA & Meijers JCM. (2011b) Evolutionary conservation of the LPS binding site of beta2-glycoprotein I. Thromb Haemost. In press. Arad A, Proulle V, Furie RA, Furie BC & Furie B. (2011) β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 117(12), 3453-3459. Bevers EM & Galli M. (1990) Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Electron microscopy analysis of β2GPI. , 2010). Analysis of EM pictures showed that more than 99% of plasma β2GPI was in a closed conformation. These observations suggested that plasma β2GPI circulates in a circular (closed) conformation, whereas after interaction with antibodies β2GPI undergoes a major conformational change into a fishhook-like (open) structure. , 1996). When antibodies toward β2GPI were added to plasma, clotting times prolonged in a β2GPI-dependent ...
The antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPA) associated with thrombosis (arterial and venous) and pregnancy morbidity. This thesis has aimed to investigate the frequency of protein C pathway defects in patients with aPA and to study clinical correlates examine the mechanisms of antiphospholipid interference in the protein C pathway and to assess activated protein C (APC) resistance in patients with aPA in terms of thrombin generation. Although have I have discovered a high degree of heterogeneity in the phenotype of patients with APS, I have demonstrated APC resistance and increased thrombin generation in the majority of patients with APS. While in some cases, APC resistance is clearly immunoglobulin mediated, it is a multifactorial phenomenon with many confounding variables. My data suggest that immunoglobulin dependent APC resistance may occur through P2 glycoprotein-I dependent and independent mechanisms. In a detailed study of ...
Erkan: Antiphospholipid Syndrome patients with vascular events generally receive life-long anticoagulation, despite the lack of high-quality data on the risk of recurrence and optimal duration of anticoagulation. Given that at least 50% of thrombotic events in aPL-positive patients have recognizable triggers, the possibility of discontinuing anticoagulation in highly selected patients exists, especially when the triggers are eliminated. However, discontinuation of anticoagulation is a critical decision that requires careful assessment of comorbidities, triggers, and residual thrombosis as well as patient education. The 13th International Congress on aPL Treatment Task Force recommended that "in cases of first venous event, low-risk aPL profile, and a known transient precipitating factor, anticoagulation could be limited to 3-6 months." Given the importance of this question, i.e., anticoagulation withdrawal in APS, the development of a multicenter clinical trial protocol to determine whether ...
A look at antiphospholipid antibody syndrome, what laboratory tests can support the diagnosis of this syndrome, what are the causes and how is it treated. ...
One of the challenges of managing patients with antiphospholipid syndrome is the prevention of rethrombosis (secondary prophylaxis). Risk stratification, i.e. traditional cardiovascular and thrombosis
This case may be coincidental or it may be that the plasminogen deficiency increased the thrombotic tendency of APS in this patient. , 1996). Biochemistry. 35(43), 1383313842. 3 Genetics of Antiphospholipid Syndrome Jesús Castro-Marrero, Eva Balada, Josep Ordi-Ros and Miquel Vilardell-Tarrés Systemic Autoimmune Diseases Research Unit, Vall dHebron University Hospital Research Institute Universitat Autónoma de Barcelona, Barcelona Spain 1. , 2006). The etiology of APS, however, is still unknown. pdf in Orphanet, INSERM MIM nº 107320). APS can involve almost any organ system, including a wide range of clinical manifestations. , 2008). 2011) Microparticles in hemostasis and thrombosis. Circ Res. 108(10), 1284-1297. Pangburn MK & Rawal N. (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans. 30(Pt 6), 1006-1010. Pennings MT, van Lummel M, Derksen RH, Urbanus RT, Romijn RA, Lenting PJ & de Groot PG. (2006) Interaction of beta2-glycoprotein I with members of the ...
In the present study, the main findings were an increase in aPL antibody levels and a number of behavioral/cognitive dysfunction and neurodegenerative changes associated with these autoantibodies in the FVL eAPS mice. These effects were linked to gene dosage, and were thus significantly more pronounced in homozygous FVLQ/Q than in heterozygous FVLQ/+ mice. The serological and behavioral effects found in the FVL mice in this study are in line with results of previous studies using other mouse strains in which eAPS was induced by immunization with β2-GPI [17, 23, 24] or immunization with a pathogenic autoantibody [25].. The pathogenesis of aPL antibody-mediated brain damage is complex, and may include thrombosis, inflammation, or direct binding of antibodies to the brain. The results of the present study do not support the presence of either thrombosis or inflammation in the FVL eAPS brain. This is in line with previous studies in the eAPS model in various wild-type strains of mice, including ...
... - also known as Hughes syndrome - is an autoimmune disorder in which the immune system attacks phospholipids.
Hi, I have often thromboses, so Im taking anticoagulants regularly. Doctors are having trouble diagnosing. Maybe I have antiphospholipid syndrome.
Antiphospholipid syndrome is a lifelong condition. Women need treatment. This will lower your chance of getting blood clots. It will also reduce your risk for problems such as stroke and miscarriage. Medicine can reduce your risk for blood clots, but they can still happen. Its important to follow your healthcare providers care plan and have tests done as often as he or she recommends. Support groups can help you meet other people with your condition. Ask your healthcare provider about support groups in your area. ...
Antiphospholipid syndrome is a lifelong condition. Women need treatment. This will lower your chance of getting blood clots. It will also reduce your risk for problems such as stroke and miscarriage. Medicine can reduce your risk for blood clots, but they can still happen. Its important to follow your healthcare providers care plan and have tests done as often as he or she recommends. Support groups can help you meet other people with your condition. Ask your healthcare provider about support groups in your area. ...
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
By combining fundamental research and monitoring a single cohort of kidney-transplant patients with antiphospholipid syndrome, the researchers have highlighted a beneficial effect of sirolimus, commonly used as an immunosuppressor in organ transplants, to prevent recurrence of vascular lesions on the transplanted kidney.
Antiphospholipid Syndrome Clinical Research Trial Listings in Hematology Immunology Obstetrics/Gynecology (Womens Health) Rheumatology on CenterWatch
Reviews and ratings for bufferin arthritis strength when used in the treatment of antiphospholipid syndrome. Share your experience with this medication by writing a review.
Autoimmune Diseases is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies on all aspects of autoimmunity. As a multidisciplinary journal, basic science aimed at understanding the biology and mechanism of disease will be considered, as well as articles focusing on medical treatment of autoimmune diseases.
Pulmonology Advisor offers the latest asthma, COPD, lung cancer, pneumonia news articles for pulmonologists and the healthcare community. Download the FREE app now.
By Kristin Bendikson, MD. When a woman has a miscarriage, she often feels isolated and alone. Miscarriages are more common than most people realize, however; and when women start talking with their friends, they often find that they are not alone in coping with this difficult experience.. A miscarriage-the early loss of a pregnancy-occurs in approximately 15 percent of all clinically recognized pregnancies. If all pregnancies are accounted for, the statistic is closer to 50 percent ending in a loss. The increase is due to the fact that many women dont even know they are pregnant and experience their period at the normal time or just a few days late. Sometimes a woman knows she is having a miscarriage because she has symptoms, which might include bleeding and cramping followed by the passage of the pregnancy. Other times a woman doesnt sense there is anything wrong at all, and she finds out that the pregnancy has stopped growing only when she sees her doctor for an ultrasound.. Its important ...
Health related message boards offering discussions of numerous health topics including allergies, cancer, diabetes, heart disease, exercise, attention deficit disorder, diet, and nutrition.
Health related message boards offering discussions of numerous health topics including allergies, cancer, diabetes, heart disease, exercise, attention deficit disorder, diet, and nutrition.
Physician assistants and nurse practitioners use Clinical Advisor for updated medical guidance to diagnose and treat common medical conditions in daily practice.
A free diabetes, endocrinology and medical news article resource for endocrinologists and physicians. Endocrinology conference coverage and drug information.
The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the main clinical features of venous and/or arterial thrombosis (intravascular blood clotting), thrombocytopenia, recurrent fetal loss, and moderate-to-high titers of antiphospholipid (aPL) antibodies, lupus anticoagulant, anti-cardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies (refs 1-2). aPL antibodies are autoantibodies that react with negatively-charged phospholipids such as cardiolipin. They are often found in the sera of patients with systemic lupus erythematosus and related diseases and are typical for the development of secondary APS. The presence of antiphospholipid antibodies in patients with no other autoimmune disease is characteristic of primary APS. Anti-cardiolipin antibodies are found in 80-90% of patients with APS. However, the presence of anti-cardiolipin antibodies are not specific to APS, because these antibodies may be detected in other autoimmune diseases, following ...
PURPOSE OF REVIEW: Laboratory criteria for the classification of antiphospholipid syndrome include the detection of a lupus anticoagulant and/or anticardiolipin and anti-β2-glycoprotein I antibodies. However, the majority of patients who test positive in these assays do not have thrombosis. Current risk-stratification tools are largely limited to the antiphospholipid antibody profile and traditional thrombotic risk factors. RECENT FINDINGS: Novel biomarkers that correlate with disease activity and potentially provide insight into future clinical events include domain 1 specific anti-β2GPI antibodies, antibodies to other phospholipids or phospholipid/protein antigens (such as anti-PS/PT), and functional/biological assays such as thrombin generation, complement activation, levels of circulating microparticles, and annexin A5 resistance ...
Results Seventy six patients with APS were included: 11 patients with primary APS and 65 patients with secondary APS, with mean disease duration of 9.59±7.39years. Overall,35 patients (46.1%) had neurologic manifestations. Their mean disease duration was 9.2±5.76 years. Seven patients had primary APS and 28 patients had secondary APS. Six patients were on chronic oral anticoagulant therapy and low dose aspirin, 12 patients on oral anticoagulant alone and 15 patients on low dose aspirin. Transient ischemic attack was the first manifestation of APS in 4 patients (11.42%) at mean age of 29.5±10.96 years. Their mean DIAPS value was 7.75±4.19. Ischemic stroke was the first APS manifestation in 12 patients (34.28%) at mean age of 40.08±16.31years, with DIAPS mean value of 7.41±3.67. All of these patients have neurological sequelaes. The DIAPS value was higher in patients with neurologic manifestations (3±2.9 vs 5.71±3.62, p=0.001) and DIAPS value correlated significantly to neurologic ...
RESULTS: Abnormal MR findings were more common in patients with systemic lupus erythematosus with antiphospholipid syndrome (73% versus 53%). Large territorial (P = .01), lacunar (P = .01), localized cortical (P , .01), borderzone infarcts (P , .01), basal ganglia lesions (P = .03), stenotic arterial lesions (P = .04), and the rate of positive findings on MR imaging (P = .01) were significantly associated with antiphospholipid syndrome. Irrespective of age, significantly more patients with antiphospholipid syndrome manifested lacunar infarcts in the deep white matter (P , .01), localized cortical infarcts in the territory of the MCA (P , .01), bilateral borderzone infarcts (P , .01), and anterior basal ganglia lesions (P = .01). ...
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder in which patients have autoantibodies to phospholipid-bound proteins (eg, beta2-glycoprotein I, prothrombin, annexin A5). The pathophysiology is not precisely known. Antiphospholipid Syndrome (APS) is an important recognised cause of acquired treatable thrombophilia. It is characterised by the core clinical manifestations of thrombosis in both venous and arterial circulation resulting in recurrent thrombotic […]. ...
BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both) and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence is estimated at 40 to 50 cases per 100,000 people. The most common sites of thrombosis are cerebral arteries and deep veins of the lower limbs. People with a definite APS diagnosis have an increased lifetime risk of recurrent thrombotic events. OBJECTIVES: To assess the effects of antiplatelet or anticoagulant agents, or both, for the secondary prevention of recurrent thrombosis, particularly ischemic stroke, in people with antiphospholipid syndrome ...
Introduction The aim of this study was to examine the prevalence and functional effects of antibodies directed against Factor (F)Xa and other serine proteases (SP) in patients with antiphospholipid...
In those with APS, the immune system fails to recognize certain blood proteins, attacking and destroying them as if they were bacteria or viruses. The destruction of these cells causes blood clots to form which can occur anywhere in the body. These clots can cause serious damage to cells and tissue depending on where they form and can break free, traveling anywhere in the body through the circulatory system. APS can also cause several complications during pregnancy. Though it is possible to have APS alone, a condition known as primary APS, many with the condition also suffer from rheumatic diseases such as lupus. When APS accompanies other disorders, it is known as secondary APS. Anyone can be affected by APS, but the disease is much more likely to affect women, with between 75 and 95 percent of those with APS being female. A higher incidence of APS is reported among African-American and Hispanic populations as well, although the reasons for this are unknown. The disorder has been recorded in ...
The Antiphospholipid Syndrome (APS) is characterized by thrombosis and pregnancy loss, clinical events mediated by pathogenic anti-phospholipid autoantibodies (aPL). β2-glycoprotein I (β2GPI) is the major autoantigens recognized by aPL. β2GPI is a cationic protein that binds to negatively charged surfaces such as those of apoptotic cells. This feature may lead to two major events: i) immunization with β2GPI fosters the Fc-receptor-mediated uptake by antigen presenting cells of apoptotic material decorated with β2GPIand the activation ofβ2GPI-specific T cells which in turn provide help to β2GPI-specific B cells for the production of anti-β2GPI; ii) apoptotic bodies decorated with β2GPI can be opsonized by anti-β2GPI and shifted towards a pro-inflammatory clearance by macrophages; epitope spread can occur with the generation of autoimmunity against nuclear autoantigens. In the presence of a predisposing genetic background and of a particular cytokine environment (type I interferons), the ...
Anti-phospholipid antibody syndrome (aPL) is a condition that promotes the formation of blood clots. In this disorder, a person may have miscarriages, unexplained blood clots in the veins or arteries (resulting in heart attack, a venous blood clot, or stroke), or a decreased platelet count.. This disorder is determined by blood tests. There is no single blood test for this disorder, a variety of different antibody measurements are made to diagnose this condition. Sometimes this disorder is associated with systemic lupus erythematosus (SLE).. People with clinical symptoms of blood clots may be treated with several medications, including heparin (or low molecular weight heparin), warfarin, or aspirin. The duration of therapy may depend on the number of clinical events they have experienced and the efficacy of these medications.. ...
A woman in her thirties suffered from lupus and antiphospholipid antibody syndrome (APS), an autoimmune, hypercoagulable disorder caused by antiphospholipid antibodies, which attack and damage tissues and cells and cause blood clots to form in the bodys arteries and veins. The woman took several anticoagulant medications as a result of a stroke she suffered at age 20. She suffered another stroke and was admitted to the hospital. She was treated at the hospital for approximately three months. About a month into her stay she underwent a kidney biopsy. After the kidney biopsy she was again administered blood-thinning therapy, including the medication Lovenox. Several days after the kidney biopsy, the woman suffered a large hemorrhage from the area of the biopsy kidney, which had become infected. As a result, the woman developed renal and respiratory failure, multiple abscesses, aspiration pneumonia, and other serious injuries and complications for which she continues to require inpatient treatment years
SLE is characterized by the production of autoantibodies that recognize a restricted subset of intracellular proteins and nucleic acids ((1)). Autoantibodies reactive with single- and double-stranded DNA, as well as nuclear RNP complexes are responsible, in part, for the ability of lupus serum to bind to the nuclei of cultured cells ((1), (5)). Antinuclear antibodies are almost always found in the serum of patients with SLE, and their presence has both diagnostic and pathogenic implications in this disease. Specific autoantibody profiles are associated with disease subsets (e.g., anti- Jo-1 histidyl tRNA synthetase and myositis) and are predictive of future disease manifestations (e.g., anti-Jo-1 and interstitial lung disease; 36, 37). Other autoantibodies have been shown to be directly pathogenic in animal models and in human disease, including anti-DNA antibodies (immune-complex glomerulonephritis), antiphospholipid antibodies (antiphospholipid antibody syndrome, characterized by arterial and ...
The INNO-LIAr ANA Update is a qualitative test detecting antibodies to several different antigens, most of which are recombinantly made, with the exception of SSA/Ro60 and histones (natural), and SmD and ribosomal P (synthetic). The LIA-SCAN ANA provides a quantitative read-out of the INNO-LIAr ANA Update results. The cut-off value of the different antigen lines was optimized using an in-house set of 955 samples. The assay specificity was validated at multiple sites using a different set of 330 samples obtained from 158 apparently healthy blood donors, 100 patients with a variety of infections, 20 with Wegeners granulomatosis, 20 with inflammatory bowel disease, 20 with primary antiphospholipid syndrome, and 12 with psoriatic arthritis. The INNO-LIAr ANA Update reactivity using the optimized cut-off was tested in 147 patients with scleroderma, 93 with Sjögrens disease, 40 patients with systemic lupus erythematosus (SLE), 40 with rheumatoid arthritis (RA), 39 with mixed connective tissue ...
For decades, scientists and clinicians have been puzzled by an autoimmune condition, antiphospholipid syndrome (APS), which causes devastating health problems including uncontrolled blood clots and repeated pregnancy loss. Recent studies have shown that naturally produced antibodies that bind to phosphatidylethanolamine (PE) are positively correlated to antiphospholipid syndrome.. Phosphatidylethanolamine (PE), a lipid that makes up 20% of the inner cell membrane, has roles in membrane trafficking and reorganization. Paradoxically, the antibodies that bind to PE (anti-PE antibodies) in APS patients are produced outside of cells. This raises the question of how do the anti-PE antibodies bind to PE without having access to their targets? To unravel this mystery, Chemistry of Life Processes Institute faculty member and Northwestern Medicine investigator Ming Zhao (cardiology) synthesized special molecular probes to investigate the dynamic distribution of PE in living cells under the microscope. The ...
PMID 19740902] Replication of association between FAM167A(C8orf13)-BLK region and rheumatoid arthritis in a Japanese population [PMID 19644876] Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome [PMID 19796918 ...
Our objectives were to evaluate thrombotic complications in patients with lupus anticoagulant fulfilling Sapporo criteria, anticoagulated with an intended INR 2.0-3.0 due to venous and arterial thrombosis. In our series standard anticoagulation was safe and efficacious in preventing recurrences in patients with systemic lupus erythematosus, with other thrombophilia and with arterial thrombosis.. ...
Although HLA class II molecules are well recognized to present peptide antigens to T cells, recently we found that ER misfolded proteins are transported to the cell surface by HLA class II molecules when they are associated with the peptide-binding groove of HLA class II molecules.32 Furthermore, intact IgG heavy chain is transported to the cell surface by HLA class II molecules via association with the peptide-binding groove, and IgG heavy chain/HLA class II complexes are recognized by autoantibodies in rheumatoid factor-positive sera from RA patients.33 In contrast, autoantibodies in rheumatoid factor-positive sera from non-RA individuals did not bind to IgG heavy chain/HLA class II complexes, suggesting that IgG heavy chain complexed with HLA-DR is a specific target for autoantibodies from RA patients. Of note, a strong correlation between autoantibody binding to IgG complexed with certain HLA-DR alleles and the odds ratio for association of these alleles with RA was observed.33 These ...
APS may contribute to an increased frequency of stroke or MI, especially in younger individuals. Strokes may develop secondary to in situ thrombosis or embolization that originates from the valvular l... more
I have APS. I was diagnosed in July 2011 after losing my son, Fritzy, on May 6th to PE and HELLP. I was 24 weeks along at the time. I started taking LDA immediately after my diagnosis because I wanted to conceive sooner than later because I was 38 at the time. In November 2011, I becamel pregnant. At 8 weeks I saw my MFM and started 40 mg twice daily lovenox. My due date was August 21. My pregnancy was very normal. My doctors were pleased at how things went. My pressures were excellent, never any protein, and only swelling in my feet at the end. I was scheduled to be induced the 39th week but Gavin came at 37 +4. He was beautiful and healthy. He is almost 18 weeks old and an absolute joy. I would suggest looking on the internet to learn more. I had the most luck with the Hughes Syndrome page. I plan to resume taking LDA when I finish breastfeeding, just as a preventive measure. Hope that was helpful ...
New York - Motivated by the lack of treatment options for patients with antiphospholipid syndrome (APS), rheumatology researchers convened an international committee to address the problem directly. Their creation, APS ACTION (Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking), is bringing together some of the foremost experts on APS-a little-known blood condition that can cause severe health consequences-to design clinical trials and registries focused on improving patient outcomes.. As a result of its first-ever meeting this past November, APS ACTION determined that distinct variations of APS-which causes frequent abnormal blood clots in arteries and veins -made patient studies into the condition very challenging. Blood clots form because the immune system mistakenly produces antibodies against phospholipid-binding plasma proteins, which puts those affected at risk for stroke and pregnancy complications.. "We concluded there are few controlled clinical trials ...
This disease can have serious effects in pregnancy, both for the mother and the baby. These include strokes, blood clots, and recurrent miscarriage.
In this study, we have used different proteomic techniques to compare and characterize multiple proteins simultaneously in Ig-treated monocytes. We identified a number of proteins that are differentially regulated by APS IgG compared with HC IgG.. Classical proteomic techniques measure the intensity of the 2D PAGE protein stain to determine individual protein quantity and confirm its identity by MS. Of the additional techniques we used, 2D DiGE overcomes limitations in traditional 2D electrophoresis due to intergel variation by allowing measurement of the abundance of a protein in each sample by direct comparison with other samples as well as an internal standard (in this case a mix of IgG from all 3 groups) on each gel.. Not all proteins, however, are amenable to 2D DiGE particularly hydrophobic membrane proteins. Therefore, to ensure that we had fully characterized the proteome, we studied tryptic digests of IgG-treated monocyte proteins using LC-MS/MS label-free quantitation on a Q-TOF mass ...
BULGULAR: Hasta grubunda 26 trombozlu (%65) AFS olgusu ve 14 (%14) trombozu olmayan AFS olgusu yer almaktad r. Hasta ve kontrol grubu k yasland nda incelenen polimorfizlerden N562D-DN genotipi hasta grubunda anlaml olarak y ksek bulunmu tur (p: 0,003). Yine hasta grubuna bak ld nda trombozlu AFS grubunda trombozu olmayan AFS grubuna k yasla N562D-DN genotipine anlaml olarak s k rastlanm t r (p: 0,03). N562D NN genotipi ise kontrol grubunda hasta grubuna oranla daha y ksek s kl ktad r (p: 0,004 ...
If your current repository username differs from your University username, please email [email protected] so we can update these details on your behalf.. Due to the change, there will be a short outage of the repository from 9am on the morning of the 1st of November. ...
I developed pre-eclampsia with my first (and only) pregnancy. I know I dont have to explain to you all what a miserable and frightening experience that was. Now my husband and I are discussing whether or not to try again. My OBGYN referred us to a perinatologist, with whom we met and discussed the risks. She recommended the extensive bloodwork that tests for clotting disorders and so we went ahead with it. My OBGYN assured me that the clotting disorders are very rare and was confident that I had a 99% chance of the results being negative ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Principal Investigator:TSUTSUMI Akito, Project Period (FY):1997 - 1999, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:内科学一般
Pain management information for pain medicine healthcare professionals in treating and caring for their patients. Clinical Pain Advisor offers news, case studies and more.
Cancer Therapy Advisor provides obsteticians and gynecologists with the latest information to correctly diagnose obgyn conditions, recommend procedures and guides. Visit often for updates and new information.
Build: Wed Jun 21 18:33:50 EDT 2017 (commit: 4a3b2dc). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
Anticoagulation is not perfect. Among patients receiving low molecular weight heparin for venous thromboembolism, approximately 5% will have a recurrence while still on Coumadin. This was repeated in a second study where 355 patients with first venous thromboembolism received unfractionated heparin that was bridged to coumadin. Most patients were treated for 3 months and recurrent event rate during that time was 4.9%. Risk factors for coumadin failure include cancer, antiphospholipid antibody syndrome and idiopathic as opposed to provoked venous thromboembolism. From a practical standpoint, coumadin failure is most commonly encountered when there is difficulty managing the INR or when patients are not compliant with the medication. This may be even worse with novel anticoagulants. As novel anticoagulants need to be taken every day or twice a day missing a dose may result in anticoagulation failure.. A study published in Thrombosis and Haemostasis in 2013 examined the long-term outcomes of ...
Founded in 2005, APS Foundation of America, Inc. (APSFA) is the only United States nonprofit health agency dedicated to bringing national awareness to Antiphospholipid Syndrome (APS), the major cause of multiple miscarriages, thrombosis, young strokes and heart attacks. We are a volunteer run, community based 501(c)3 non-profit Public Charity organization and is dedicated to fostering and facilitating joint efforts in the areas of education, support, public awareness, research and patient services. The APSFAs Medical Advisory Team includes nationally & internationally recognized experts on Antiphospholipid Syndrome.. APS is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. There are two known forms. APS may occur in people with systemic lupus erythematosus, other autoimmune disease, or in otherwise healthy individuals.. APS is also referred to as APLS or APLA in the United ...
And given that that progestin-releasing IUDs do not increase the risk for blood clots [ref 1], it is a particularly attractive option in women with a history of blood clots (DVT, PE, etc) or a clotting disorder (= thombophilia or hypercoagulable states), such as factor V Leiden, the prothrombin (factor II) mutation, or protein C, S or antithormbin deficiency or the antiphospholipid antibody syndrome. Thrombosis is not listed as a possible adverse outcome associated with Skyla® use ...
vitamin K dependent cofactors in the extrinsic coagulation cascade. Dosing is guided by measuring the international normalized ratio (INR), and most patients are therapeutic in a range of 2 to 3. Patients with mechanical heart valves or antiphospholipid antibody syndrome require an INR of 2.5 to 3.5. It takes about 3 to 4 days to reach full anticoagulation upon initiating treatment. A parenteral anticoagulant should be used until the INR is maintained in the desired range for 2 days as warfarin therapy causes a transient state of thrombogenesis at the start of therapy. A number of medications, foods, or disease states interfere with warfarin absorption or metabolism and cause clinically significant consequences. Warfarin use is contraindicated during pregnancy due to teratogenicity. Complications of warfarin use include bleeding from over-anticoagulation, increased bleeding risk in patients with hypertension, anemia, prior cerebrovascular disease, GI lesions, and renal disease. Skin necrosis is ...
Glycemia and insulinemia in healthy subjects after lactose-equivalent capacity to stimulate insulin release of foods: the insulin demand generated Which test strips can you use with the free meter? OneTouch Verio Test Strips Around 3.7 million people in the UK have diabetes yet according to Diabetes UK One or both eyes may be affected. Diabetes Blood Test Results That means type 2 medication treatment solutions are big line of work. Tilda Rizazz Rice health Concern On Your Mind? Diabetic Rash On Legs ::The 3 Step Trick that Reverses Diabetes Permanently in As Little as 11 Days. Systemic lupus erythematosus (SLE) Pancreatitis in lupus is uncommon and could occur in a setting of high SLEDAI scores antiphospholipid antibody syndrome Diabetes Care Pathway NICE for the management of diabetes for patients with type 2 diabetes that may have been avoided NovoRapid vials prefilled pens (FlexPen and Flextouch pens) and penfill cartridges (for use with NovoPens) all contain the active ingredient insulin ...
Do You Have Antiphospholipid Ant? Join friendly people sharing true stories in the I Have Antiphospholipid Ant group. Find support forums, advice and chat with groups who share this life experience.
Is there anyone in here with a child who has Antiphospholipid Antibody Syndrome? My daughter was diagnosed at age 10. Now shes almost 12. It would just be nice...
When conducting a comprehensive survey of spouses for habitual miscarriage, the first task of a specialist is to assess congenital factors predisposing to the development of high-risk thrombophilia.. - A blood test of spouses for compatibility with the HLA Class II system is also being conducted. We will explain a little. Immune mechanisms are involved in the development of recurrent miscarriage. Each person is unique in the set of HLA-determinants (tissue compatibility system). For the normal course of pregnancy, an important factor is the maximum difference between parents in the histocompatibility analysis. If this indicator is normal, then other risk factors are assessed.. - During the examination, a blood test is also assigned for the diagnosis of antiphospholipid syndrome (APS), a test for lupus anticoagulant (BA). Antiphospholipid antibodies have a direct damaging effect on the ovum with a further development of spontaneous abortion. The complex for the diagnosis of APS includes an ...
Doruk Erkan and colleagues studied rituximab in antiphospholipid syndrome. "The primary objective of this pilot, open-label, Phase II study was to evaluate the safety of rituximab in 20 aPL-positive patients, as assessed by serious and non-serious adverse events (AE) (up to 12 months [m])." Two patients out of 19 developed infusion reactions, which I think is a high number; the study does not reflect about the issue of a special risk. They counted 59 AEs (12 serious with hospitalizations, but interpreted these as "unlikely" to be related to rituximab, 7 non-serious within 48h of infusion were interpreted as "likely". Even if unrelated to rituximab is correct, Ive never seen as many AEs, especially with hospitalization is my own patients (rheumatoid arthritis), so I think that this is another hint to look into special risks for aPL-positive patients treated with rituximab. There were some effects on aPL-tests, but not convincing as the largest effects are in the smallest groups (down to n=2). In ...
Sindroma Antiphospholipid (APS) - eshte nje semundje autoimmune karakterizuar nga perpunimin e sasive te medha te antitrupave me fosfolipide - strukturat kimike të cilat janë ndërtuar të qelizave...
OBJECTIVE: The preliminary classification criteria for antiphospholipid syndrome (APS), or the Sapporo criteria, are widely used for the inclusion of patients with APS into clinical studies. Revised Sapporo criteria have been proposed as an improved criteria set. Whether these criteria sets fulfill the current standards of measurement science are unknown. The purpose of this study was (1) to evaluate the developmental methodology and measurement properties of the Sapporo and the revised Sapporo criteria for use in clinical trials; and (2) to evaluate if the revised Sapporo criteria provide added value over the Sapporo criteria. METHODS: A computer search for articles describing use of the Sapporo and the revised Sapporo criteria was performed. Item generation, item reduction, sensibility, validity, and reliability of the criteria were evaluated. RESULTS: The Sapporo criteria set has incremental face and content validity over its predecessors. However, through separation of anti-ss2-glycoprotein ...
My husband, 35, was recently diagnosed with Antiphospholipid Syndrome and Lupus Anticoagulant syndrome... Heres his story, I am hoping to find any men that can...
TY - JOUR. T1 - Efficacy of eculizumab in a patient with immunoadsorption- dependent catastrophic antiphospholipid syndrome. T2 - A case report. AU - Kronbichler, Andreas. AU - Frank, Renate. AU - Kirschfink, Michael. AU - Szilágyi, Ágnes. AU - Csuka, Dorottya. AU - Prohászka, Z.. AU - Schratzberger, Peter. AU - Lhotta, Karl. AU - Mayer, Gert. PY - 2014/11/14. Y1 - 2014/11/14. N2 - Catastrophic antiphospholipid syndrome (CAPS) is a rare but devastating complication in patients with antiphospholipid syndrome (APS) with a high morbidity and mortality. We describe a case of a 30-year old female patient with immunoglobulin A (IgA) deficiency who underwent splenectomy because of idiopathic thrombocytopenic thrombocytopenia. Subsequently, an APS and finally systemic lupus erythematosus was diagnosed. After an uncomplicated pregnancy that was terminated by cesarean section, the patient developed severe CAPS with cerebral, myocardial, renal, and pulmonary involvement. Because of IgA deficiency, ...
Looking for online definition of anticardiolipin antibody syndrome in the Medical Dictionary? anticardiolipin antibody syndrome explanation free. What is anticardiolipin antibody syndrome? Meaning of anticardiolipin antibody syndrome medical term. What does anticardiolipin antibody syndrome mean?
BACKGROUND AND OBJECTIVES:. Vascular disease is common in systemic lupus erythematosus (SLE) and patients with antiphospholipid antibodies (aPL) are at high risk to develop arterial and venous thrombosis. Since HLA class II genotypes have been linked to the presence of pro-thrombotic aPL, we investigated the relationship between HLA-DRB1 alleles, aPL and vascular events in SLE patients.. METHODS:. 665 SLE patients of Caucasian origin and 1403 controls were included. Previous manifestations of ischaemic heart disease, ischaemic cerebrovascular disease (ICVD) and venous thromboembolism (together referred to as any vascular events (AVE)) were tabulated. aPL were measured with ELISA. Two-digit HLA-DRB1 typing was performed by sequence-specific primer-PCR.. RESULTS: HLA-DRB1*04 was more frequent among SLE patients with ICVD compared to unaffected patients. This association remained after adjustment for known traditional cardiovascular risk factors. HLA-DRB1*13 was associated with AVE. All measured ...
A prospective study of IgG and IgM isotypes of anticardiolipin antibodies (aCL) in a series of 100 patients with systemic lupus erythematosus was carried out. To determine the normal range of both isotype titres a group of 100 normal control serum samples was studied and a log-normal distribution of IgG and IgM isotypes was found. The IgG anticardiolipin antibody serum was regarded as positive if a binding index greater than 2.85 (SD 3.77) was detected and a binding index greater than 4.07 (3.90) was defined as positive for IgM anticardiolipin antibody. Twenty four patients were positive for IgG aCL, 20 for IgM aCL, and 36 for IgG or IgM aCL, or both. IgG aCL were found to have a significant association with thrombosis and thrombocytopenia, and IgM aCL with haemolytic anaemia and neutropenia. Specificity and predictive value for these clinical manifestations increased at moderate and high anticardiolipin antibody titres. In addition, a significant association was found between aCL and the ...
HLA-DR12(DR12) is a HLA-DR serotype that recognizes the DRB1*1201 to *1203, *1206. DR12 serotype is a split antigen of the older HLA-DR5 serotype group which also contains the similar HLA-DR11 antigens. The table above describes the efficiency of serological typing of DR12 and DR5. Serotypes are unknown the following alleles: DRB1*1204,*1205 to *1207 to *1215 There are only 2 common allels for DRB1*12, *1201 and *1202. *1202 is more common on the West Pacific Rim and particularly Indochina and the South Pacific. DR12 is associated with vulval lichen sclerosus, and undifferentiated spondyloarthritis. DRB1*1201 is associated with iritis in juvenile arthritis, primary antiphospholipid syndrome, tiopronin intolerance in rheumatoid arthritis, adult chronic articular Stills disease DRB1*1202 is found to be increased in narcolepsy associated sudden death syndrome in the Thai population, and narcolepsy in the Japanese population. DRB1*12:DQA1*0505:DQBA1*0301 haplotype: DR12-DQ7.5/DR7-DQ2.2 is a ...
Recurrent pregnancy loss (RPL) can be defined as more than two to three consecutive miscarriages before 24 weeks gestation. A literature review was done to provide an evidence-based approach to RPL, identifying the risk factors and causes and also looking at the various special investigations that form part of the work-up and trying to assess which have been proven to be effective or of negative impact, and which of the management options lead to a better outcome. We concluded that the following special investigations should be part of the work-up for all patients with RPL: (i) genetic counselling and karyotyping of the abortus; (ii) anticardiolipin antibodies and lupus anticoagulant testing must be done on two occasions, 6 - 8 weeks apart; (iii) all patients qualify for a pelvic ultrasound scan and hysteroscopy; (iv) syphilis testing must be done routinely; and (v) testing of thyroid function and glucose monitoring/glycosylated haemoglobin (HbA1c) measurement must be done in all patients with ...
J, Goh K and V, Subrayan and I, Tajunisah (2007) Antiphospholipid Syndrome Manifesting as Papilloedema. International Journal Of Ophthalmology, 7. pp. 1522-5. J, Goh K (2007) Serological evidence of possible human infection with Tioman virus, a newly described paramyxovirus of bat origin. The Journal of Infectious Disease, 196 (6). pp. 884-6. J, Goh K (2005) Oculopharyngeal muscular dystrophy with PABPN1 mutation in a Chinese Malaysian woman. pp. 262-4. J, Goh K (2005) The long-term outcome of botulinum toxin A treatment for hemifacial spasm in Malaysian patients. pp. 105-8. J, Goh K (2004) Covert use of anticonvulsant medication in traditional Chinese medication used for the treatment of epilepsy. pp. 55-7. J, Goh K (2004) The clinical spectrum of Malaysian patients with chronic inflammatory demyelinating polyneuropathy. Neurology Asia, 9. pp. 33-7. J, Goh K (2004) The clinical syndrome associated with lumbar spinal stenosis. European Neurology, 52. pp. 242-9. J, Goh K (2003) Symptomatic ...
TY - JOUR. T1 - Concurrent lupus anticoagulants and prothrombin defiency due to phenytoin use. AU - Harrison, R. L.. AU - Alperin, J. B.. AU - Kumar, D.. PY - 1987. Y1 - 1987. N2 - A man with a lupus anticoagulant and a prothrombin deficiency was studied before and after cessation of treatment with phenytoin. Multiple abnormal laboratory values of the following partially or completely resolved after the patients therapy was discontinued: tissue thromboplastin inhibition ratio, prothrombin time, activated partial thromboplastin time, anticardiolipin antibodies, and quantitative measures and abnormal pattern on crossed immunoelectrophoresis of prothrombin. This patient represented an example of a concurrent drug-induced prothrombin deficiency and a lupus anticoagulant.. AB - A man with a lupus anticoagulant and a prothrombin deficiency was studied before and after cessation of treatment with phenytoin. Multiple abnormal laboratory values of the following partially or completely resolved after the ...
In this cohort of 519 patients, 60 (11.6%) had epileptic seizures associated with SLE disease activity. The frequency of epileptic seizures in previous studies ranged between 8.3 and 28%.1,5-10,21⇓⇓⇓⇓⇓⇓⇓ Epileptic seizures at disease onset were identified in 19 (31.7%) of these 60 patients. Epileptic seizures occurred after the onset of the disease in 41 (68.3%) patients. Fifty-three (88.3%) patients had a single epileptic seizure episode, and 7 (11.7%) had recurrent epileptic seizures. Generalized tonic-clonic and complex partial seizures were the most common epileptic seizures observed in this study. At disease onset, epileptic seizures were associated with stroke and the presence of moderate to higher titers of IgG antiphospholipid antibodies. The association between higher titers of antiphospholipid antibodies and seizures has been demonstrated previously.2,4,9,22-26⇓⇓⇓⇓⇓⇓⇓. Epileptic seizures may occur in isolation or accompany other neurologic ...

Antiphospholipid syndrome - WikipediaAntiphospholipid syndrome - Wikipedia

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused ... Antiphospholipid syndrome can be primary or secondary. Primary antiphospholipid syndrome occurs in the absence of any other ... Antiphospholipid syndrome is an autoimmune disease, in which "antiphospholipid antibodies" (anticardiolipin antibodies and ... "catastrophic antiphospholipid syndrome" (CAPS or Asherson syndrome) and is associated with a high risk of death. ...
more infohttps://en.wikipedia.org/wiki/Antiphospholipid_syndrome

Catastrophic Antiphospholipid Syndrome And Heparin Induced Thrombocytopenia: Related Diseases Or Chance Association? | 19900Catastrophic Antiphospholipid Syndrome And Heparin Induced Thrombocytopenia: Related Diseases Or Chance Association? | 19900

Catastrophic Antiphospholipid syndrome (CAPS) and heparin-induced thrombocytopenia (HIT) are immune- mediated thrombotic ... Catastrophic antiphospholipid syndrome and heparin induced thrombocytopenia: Related diseases or chance association?. ... Introduction: Catastrophic Antiphospholipid syndrome (CAPS) and heparin-induced thrombocytopenia (HIT) are immune- mediated ...
more infohttps://www.omicsonline.org/proceedings/catastrophic-antiphospholipid-syndrome-and-heparin-induced-thrombocytopenia-related-diseases-or-chance-association-19900.html

PatientsLikeMe | Antiphospholipid antibody syndrome symptoms, treatments & patient forums | PatientsLikeMePatientsLikeMe | Antiphospholipid antibody syndrome symptoms, treatments & patient forums | PatientsLikeMe

640 patients with antiphospholipid antibody syndrome experience fatigue, Pain, depressed mood, anxious mood, and insomnia and ... Find the most comprehensive real-world symptom and treatment data on antiphospholipid antibody syndrome at PatientsLikeMe. ... and Oxycodone to treat their antiphospholipid antibody syndrome and its symptoms. ... What is antiphospholipid antibody syndrome?. Antiphospholipid syndrome, Hughes syndrome, or antiphospholipid antibody syndrome ...
more infohttps://www.patientslikeme.com/conditions/515-antiphospholipid-antibody-syndrome

Efficacy of eculizumab in a patient with immunoadsorption- dependent catastrophic antiphospholipid syndrome: A case report<...Efficacy of eculizumab in a patient with immunoadsorption- dependent catastrophic antiphospholipid syndrome: A case report<...

Catastrophic antiphospholipid syndrome (CAPS) is a rare but devastating complication in patients with antiphospholipid syndrome ... "Catastrophic antiphospholipid syndrome (CAPS) is a rare but devastating complication in patients with antiphospholipid syndrome ... Catastrophic antiphospholipid syndrome (CAPS) is a rare but devastating complication in patients with antiphospholipid syndrome ... Catastrophic antiphospholipid syndrome (CAPS) is a rare but devastating complication in patients with antiphospholipid syndrome ...
more infohttps://hungary.pure.elsevier.com/en/publications/efficacy-of-eculizumab-in-a-patient-with-immunoadsorption-depende

Protein Z Deficiency in Antiphospholipid-Negative Sneddons Syndrome | StrokeProtein Z Deficiency in Antiphospholipid-Negative Sneddon's Syndrome | Stroke

Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore). 1999; ... Protein Z Deficiency in Antiphospholipid-Negative Sneddons Syndrome. Nakhlé Ayoub, Gaetan Esposito, Stéphane Barete, Claudine ... Protein Z Deficiency in Antiphospholipid-Negative Sneddons Syndrome. Nakhlé Ayoub, Gaetan Esposito, Stéphane Barete, Claudine ... Protein Z Deficiency in Antiphospholipid-Negative Sneddons Syndrome. Nakhlé Ayoub, Gaetan Esposito, Stéphane Barete, Claudine ...
more infohttp://stroke.ahajournals.org/content/35/6/1329

Learn about Antiphospholipid Antibody Syndrome and the Symptoms it can CauseLearn about Antiphospholipid Antibody Syndrome and the Symptoms it can Cause

Learn about the diverse effects antiphospholipid antibody syndrome (APS) can have, from heart attack to miscarriage and how APS ... Antiphospholipid antibody syndrome is a fascinatingly complex disorder. It is an autoimmune disease, whereby the immune system ... What is Antiphospholipid Antibody Syndrome (APS)?. One of the main targets of the immune response in APS is a protein called b( ... Antiphospholipid Syndrome (APS): Where does it come from? Y.Sherer, M. Blank & Y Shoenfeld, Best Practice and Research Clinical ...
more infohttp://www.healthguideinfo.com/autoimmune-immune-disorders/p66527/

Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis<...Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis<...

We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months ... We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months ... keywords = "Anticoagulation, Antiphospholipid antibody syndrome, Bioprosthetic valve thrombosis, Thrombolytics",. author = " ... We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months ...
more infohttps://nebraska.pure.elsevier.com/en/publications/bioprosthetic-mitral-valve-thrombosis-complicating-antiphospholip

Sneddons syndrome: it is all in the ectoderm | Practical NeurologySneddon's syndrome: it is all in the ectoderm | Practical Neurology

Repeated serum antiphospholipid antibody titres were negative. The clinical features, skin biopsy and angiogram findings ... Clinicians should consider Sneddons syndrome in patients with livedo reticularis and stroke. There are treatment dilemmas in ... strongly supported a diagnosis of Sneddons syndrome. ...
more infohttp://pn.bmj.com/content/16/4/300

Antiphospholipid Syndrome | SpringerLinkAntiphospholipid Syndrome | SpringerLink

This new edition is a comprehensive and updated resource on antiphospholipid syndrome (APS), which is an autoimmune disorder. ... antiphospholipid antibody antiphospholipid syndrome autoimmune disorder obstetric antiphospholipid syndrome pulmonary ... 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report ... 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report ...
more infohttps://link.springer.com/book/10.1007%2F978-3-319-55442-6

Antiphospholipid syndrome | The BMJAntiphospholipid syndrome | The BMJ

... www.hughes-syndrome.org) is the only UK registered charity dedicated to helping people affected by antiphospholipid syndrome. ... Tracy Jallow patient living with antiphospholipid syndrome, David DCruz professor, Heidi Lempp senior lecturer in medical ... This visual aid lets people know that I am unwell as antiphospholipid syndrome is mostly invisible to others. I had to learn to ... When I finally got a diagnosis of antiphospholipid syndrome I requested access to my GP records to look for clues or things ...
more infohttps://www.bmj.com/content/350/bmj.h1426

Antiphospholipid syndrome - APS: MedlinePlus Medical EncyclopediaAntiphospholipid syndrome - APS: MedlinePlus Medical Encyclopedia

Antiphospholipid syndrome (APS) is an autoimmune disorder that involves frequent blood clots (thromboses). When you have this ... Antiphospholipid antibody syndrome. www.nhlbi.nih.gov/health-topics/antiphospholipid-antibody-syndrome. Accessed June 5, 2019. ... 14th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome. ... ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS). In general, you will need treatment with a blood thinner for a long time if you have ...
more infohttps://medlineplus.gov/ency/article/000547.htm

Antiphospholipid Syndrome Clinical Research Trials | CenterWatchAntiphospholipid Syndrome Clinical Research Trials | CenterWatch

Antiphospholipid Syndrome Clinical Research Trial Listings in Hematology Immunology Obstetrics/Gynecology (Womens Health) ... Antiphospholipid Syndrome Clinical Trials. A listing of Antiphospholipid Syndrome medical research trials actively recruiting ...
more infohttps://www.centerwatch.com/clinical-trials/listings/condition/542/antiphospholipid-syndrome/?NewOnly=Y

Antiphospholipid Syndrome Clinical Research Trials | CenterWatchAntiphospholipid Syndrome Clinical Research Trials | CenterWatch

Antiphospholipid Syndrome Clinical Research Trial Listings in Hematology Immunology Obstetrics/Gynecology (Womens Health) ... Antiphospholipid Syndrome Clinical Trials. A listing of Antiphospholipid Syndrome medical research trials actively recruiting ... Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome ...
more infohttps://www.centerwatch.com/clinical-trials/listings/condition/542/antiphospholipid-syndrome/?&study_type=Interventional

Primary Adrenal Failure due to Antiphospholipid SyndromePrimary Adrenal Failure due to Antiphospholipid Syndrome

... Murat Sahin,1 Ayten Oguz,1 Dilek Tuzun,1 Serife Nur Boysan,2 Bülent ... G. P. Mo, P. Germaine, J. Mastoris, and D. H. Henry, "Adrenal hemorrhage associated with antiphospholipid antibody syndrome," ... R. Cervera, J.-C. Piette, J. Font et al., "Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of ... G. Espinosa, E. Santos, R. Cervera et al., "Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic ...
more infohttps://www.hindawi.com/journals/crie/2015/161497/ref/

Antiphospholipid Syndrome and Pregnancy | NorthShoreAntiphospholipid Syndrome and Pregnancy | NorthShore

Read our Antiphospholipid Syndrome and Pregnancy encyclopedia resources online. ... Antiphospholipid Syndrome and Pregnancy. Topic Overview. Antiphospholipid syndrome is a rare autoimmune disease that has been ... Pregnant women with antiphospholipid syndrome are treated with blood-thinning medicines to prevent clotting problems and ... This syndrome increases blood clotting. It can cause dangerous blood clots (thrombosis) and problems with blood flow. For some ...
more infohttps://www.northshore.org/healthresources/encyclopedia/encyclopedia.aspx?DocumentHwid=tn7432

Conversion of Discoid Lupus to Antiphospholipid Syndrome and SLEConversion of Discoid Lupus to Antiphospholipid Syndrome and SLE

A rare conversion of discoid lupus to antiphospholipid syndrome and systemic lupus erythematosus is presented in a 64-year-old ... cerebral thromboses associated with antiphospholipid syndrome (APS) and hypertension. After admission to hospital, he developed ... His clinical interests are in the assessment of patients with lupus, myositis and Sjögrens syndrome and his basic research ...
more infohttps://www.medscape.com/viewarticle/572791

Antiphospholipid syndrome - The Full WikiAntiphospholipid syndrome - The Full Wiki

... "catastrophic antiphospholipid syndrome" (CAPS).. Antiphospholipid syndrome is sometimes referred to as Hughes syndrome after ... Antiphospholipid syndrome (APS or APLS) or antiphospholipid antibody syndrome is a disorder of coagulation that causes blood ... Antiphospholipid syndrome is an autoimmune disease, in which "antiphospholipid antibodies" (Anticardiolipin antibodies and ... Antiphospholipid syndrome can cause (arterial/venous) blood clots (in any organ system) or pregnancy-related complications. In ...
more infohttp://www.thefullwiki.org/Antiphospholipid_syndrome

Antiphospholipid SyndromeAntiphospholipid Syndrome

... also known as Hughes syndrome - is an autoimmune disorder in which the immune system attacks phospholipids. ... The Latest in Antiphospholipid Syndrome. Antiphospholipid Syndrome. What Is Antiphospholipid Syndrome?. This condition can ... Antiphospholipid syndrome; Genetics Home Reference.. *What Is Antiphospholipid Antibody Syndrome? National Heart, Lung, and ... Antiphospholipid Syndrome Treatment. Antiphospholipid syndrome is treated with medications called blood thinners, which can ...
more infohttps://www.everydayhealth.com/antiphospholipid-syndrome/guide/

JCI -
Tracing the molecular pathogenesis of antiphospholipid syndromeJCI - Tracing the molecular pathogenesis of antiphospholipid syndrome

Downloading a figure as powerpoint requires a browser with javascript support. Enable javascript and try again For help please contact [email protected] ...
more infohttps://www.jci.org/assets/247278/powerpoint

Antiphospholipid syndrome (APS) | healthdirectAntiphospholipid syndrome (APS) | healthdirect

Antiphospholipid syndrome (APS) is a blood disorder that increases the risk of developing blood clots or having problems during ... Antiphospholipid syndrome: Whats to know), Melbourne Haematology (Antiphospholipid syndrome), Mayo Clinic (Antiphospholipid ... Antiphospholipid syndrome (APS) is a blood disorder that puts a person at greater risk of developing blood clots or having ... Antiphospholipid antibodies - Lab Tests Online AU. Information on when the test is used, is requested and what the test results ...
more infohttps://www.healthdirect.gov.au/antiphospholipid-syndrome

What are treatments for pregnant women with antiphospholipid syndrome (APS)?What are treatments for pregnant women with antiphospholipid syndrome (APS)?

How can blood thinners help with treating antiphospholipid syndrome (APS)?. NEXT QUESTION: What are things I can do to help ... What are treatments for pregnant women with antiphospholipid syndrome (APS)?. ANSWER Pregnant women with APS get injections of ... American College of Rheumatology: "Antiphospholipid Syndrome.". APS Foundation of America: "Antiphospholipid Antibody Syndrome ... American College of Rheumatology: "Antiphospholipid Syndrome.". APS Foundation of America: "Antiphospholipid Antibody Syndrome ...
more infohttps://www.webmd.com/dvt/qa/what-are-treatments-for-pregnant-women-with-antiphospholipid-syndrome-aps

Plasma Exchange in the Management of Catastrophic Antiphospholipid SyndromePlasma Exchange in the Management of Catastrophic Antiphospholipid Syndrome

... macrophage activation syndrome, Stills disease, septic shock and catastrophic antiphospholipid syndrome," BMC Medicine, vol. ... N. Costedoat-Chalumeau, L. Arnaud, D. Saadoun et al., "Catastrophic antiphospholipid syndrome," La Revue de Médecine Interne, ... Plasma Exchange in the Management of Catastrophic Antiphospholipid Syndrome. Dimitri Titeca-Beauport,1,2 Valery Salle,3 Loay ... G. E. Westney and E. N. Harris, "Catastrophic antiphospholipid syndrome in the intensive care unit," Critical Care Clinics, vol ...
more infohttps://www.hindawi.com/journals/cricc/2016/5375080/ref/

Antiphospholipid syndrome | DermNet NZAntiphospholipid syndrome | DermNet NZ

Antiphospholipid syndrome. Authoritative facts about the skin from DermNet New Zealand. ... What is antiphospholipid syndrome?. Antiphospholipid syndrome is an acquired autoimmune disorder characterised by recurrent ... Who gets antiphospholipid syndrome?. Antiphospholipid syndrome is generally diagnosed in young to middle-aged adults. However, ... Eye disorders in antiphospholipid syndrome. *Blindness. Blood abnormalities in antiphospholipid syndrome. *Thrombocytopenia ( ...
more infohttps://dermnetnz.org/topics/antiphospholipid-syndrome

Search of: Antiphospholipid syndrome - Results on Map - ClinicalTrials.govSearch of: Antiphospholipid syndrome - Results on Map - ClinicalTrials.gov

Click on a [studies] link to search within your current results for studies in that region. Use the back button to return to this list and try another region ...
more infohttps://www.clinicaltrials.gov/ct2/results/map?term=Antiphospholipid+syndrome&

Antiphospholipid syndrome - Renal and Urology NewsAntiphospholipid syndrome - Renal and Urology News

Antiphospholipid syndrome *What every physician needs to know:*Are you sure your patient has antiphospholipid syndrome? What ... Antiphospholipid syndrome What every physician needs to know:. Antiphospholipid (antibody) syndrome (APS) is a prothrombotic ... Beware of other conditions that can mimic antiphospholipid syndrome:. Other conditions that can mimic antiphospholipid syndrome ... Are you sure your patient has antiphospholipid syndrome? What should you expect to find?. The key symptoms and signs of APS ...
more infohttps://www.renalandurologynews.com/home/decision-support-in-medicine/hematology/antiphospholipid-syndrome-2/
  • Antiphospholipid syndrome often requires treatment with anticoagulant medication such as heparin to reduce the risk of further episodes of thrombosis and improve the prognosis of pregnancy. (wikipedia.org)
  • Secondary antiphospholipid syndrome occurs with other autoimmune diseases, such as systemic lupus erythematosus (SLE). (wikipedia.org)
  • Risk factors for developing antiphospholipid syndrome include:[citation needed] Primary APS genetic marker HLA-DR7 Secondary APS SLE or other autoimmune disorders Genetic markers: HLA-B8, HLA-DR2, HLA-DR3 Race: Blacks, Hispanics, Asians, and Native Americans There is an additional elevated risk of adrenal gland bleeds leading to Waterhouse-Friderichsen syndrome (Neisseria meningitidis caused primary adrenal insufficiency). (wikipedia.org)
  • Antiphospholipid syndrome can be primary or secondary. (wikipedia.org)
  • The syndrome can be divided into primary (no underlying disease state) and secondary (in association with an underlying disease state) forms. (wikipedia.org)
more